In 2010, researchers concluded that genotyping for TPMT in idiopathic pulmonary fibrosis (IPF) could be cost-effective if the incidence of intermediate or poor metabolizers exceeded 12.5% [4]. This evidence concerns the gene TPMT and pulmonary fibrosis.